This inventor holds 1 USPTO granted patent. Top assignee: Glaxosmithkline Intellectual Property Development Limited. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Megan Ketchum: Innovator in Cancer Treatment
Introduction
Megan Ketchum is a prominent inventor based in Collegeville, PA (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target DNA methyltransferase 1 (DNMT1). Her innovative work aims to address critical health issues, including cancer and related disorders.
Latest Patents
Megan Ketchum holds 1 patent for her invention titled "Substituted pyridines as DNMT1 inhibitors." This invention focuses on substituted pyridine derivatives that inhibit the activity of DNMT1. The patent also encompasses pharmaceutical compositions that include these compounds and outlines methods for their use in treating cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases linked to inappropriate DNMT1 activity.
Career Highlights
Megan is associated with GlaxoSmithKline Intellectual Property Development Limited, where she continues to advance her research and development efforts. Her work is pivotal in the pharmaceutical industry, contributing to innovative solutions for complex medical challenges.
Collaborations
Megan collaborates with esteemed colleagues, including Andrew B Benowitz and David T Fosbenner. Their combined expertise enhances the research and development process, fostering innovation in the field.
Conclusion
Megan Ketchum's contributions to the pharmaceutical industry exemplify the impact of innovative thinking in addressing significant health challenges. Her work on DNMT1 inhibitors represents a promising avenue for cancer treatment and other related disorders.